Parabilis Medicines’ blockbuster IPO underscores a renewed surge in biotech listings, with record-sized capital raising despite ongoing macro uncertainty. The story reports that Parabilis secured about $670 million when it hit the Nasdaq, helping extend a run of very large biotech offerings that began earlier with Kailera Therapeutics’ $625 million IPO. It also notes that other companies such as Avalyn Pharma, Seaport Therapeutics, and Odyssey Therapeutics attempted public-market fundraises. Industry commentary attributed the comeback to a multi-year gap in public and Big Pharma capital deployment after the pandemic, followed by a backlog of venture funding seeking an exit through IPOs and acquisitions. For investors and operators, the pricing and scale of new listings can influence how late-stage financing is structured and how quickly companies may access public equity capital for pipeline buildout.